Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Zootaxa ; 3750: 89-94, 2013 Dec 17.
Artículo en Inglés | MEDLINE | ID: mdl-25113680

RESUMEN

Thoracochirus yunxianius sp. nov. is described from Yunnan, China. Color images of the habitus and aedeagus of the new species are included. A key to the genus Thoracochirus of mainland China species is provided.


Asunto(s)
Escarabajos/clasificación , Distribución Animal , Estructuras Animales , Animales , China , Escarabajos/anatomía & histología , Ecosistema , Femenino , Masculino
2.
Chin Med J (Engl) ; 125(10): 1690-4, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22800885

RESUMEN

BACKGROUND: Dipeptidyl peptidase-IV (DPP-4) inhibitors are now used to improve postprandial glycemic control in type 2 diabetes. However, their effects on hepatic glucose production (HGP) in obesity are not clear. This study was designed to test the hypothesis that gluconeogenesis and HGP can be modulated by DPP-4 inhibitors in obesity. METHODS: Sprague Dawley male rats were divided into four groups, each on a different diet: general rat chow, n = 10 (G); G + sitagliptin, n = 10; high fat chow (obesity), n = 10 (55% fat calories, HFO); HFO + sitagliptin, n = 10. After 10 weeks, the rats were fasted overnight and glucose metabolism was determined using 3-(3)H-glucose and (14)C-glycerol as tracers. RESULTS: Glycerol rate of appearance (P < 0.00001), plasma glycerol (P < 0.05) and free fatty acid (FFA) (P < 0.05) concentrations, and HGP (P < 0.05) were decreased in HFO + sitagliptin group compared with HFO group, but there was no significant difference between G and G + sitagliptin groups (P > 0.05). Gluconeogenesis in HFO group was five times of that in G rats (P < 0.01), but was significantly declined in HFO + sitagliptin group (P < 0.0001). CONCLUSIONS: Gluconeogenesis and HGP were inhibited by sitagliptin in high fat-induced obese rats due to decreased glycerol availability, which was a result of reduced glycerol release from adipose tissues. The finding suggests that sitagliptin is potentially useful for controlling fasting glucose in obesity, thereby delaying or preventing the development of diabetes.


Asunto(s)
Inhibidores de la Dipeptidil-Peptidasa IV/uso terapéutico , Glucosa/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Obesidad/tratamiento farmacológico , Obesidad/metabolismo , Pirazinas/uso terapéutico , Triazoles/uso terapéutico , Animales , Masculino , Ratas , Ratas Sprague-Dawley , Fosfato de Sitagliptina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA